LONDON — May 11, 2026 — The genetics sector is in the middle of an infrastructure transition that most boardrooms have yet to fully register: the move from artisanal, lab-centric workflows to industrialised, software-defined platforms capable of operating at population scale. Illumina, CRISPR Therapeutics, and a growing cohort of computational biology firms are accelerating the shift, creating new competitive dynamics across therapeutics, diagnostics, agriculture, and enterprise data services.

Executive Summary

• The global genetics market is projected to exceed $95 billion by 2028, with sequencing infrastructure and gene-editing therapeutics as the fastest-growing segments, according to Grand View Research estimates.
• Illumina's latest NovaSeq X Plus chemistry cycles have pushed whole-genome sequencing costs below $150 per sample at high throughput, fundamentally altering health-system economics.
• CRISPR Therapeutics and Vertex Pharmaceuticals continue to expand the clinical footprint of Casgevy, the first approved CRISPR-based therapy, while next-generation editing platforms from Beam Therapeutics and Prime Medicine advance through mid-stage trials.
• Computational genetics — the fusion of machine learning and large-scale genomic datasets — is attracting enterprise investment from cloud hyperscalers and insurance groups alike.
• Regulatory frameworks in the EU, US, and UK are converging towards clearer pathways for both somatic gene therapies and genomic data governance, reducing one of the sector's largest adoption barriers.

Key Takeaways

• Sequencing cost deflation is now outpacing Moore's Law, creating entirely new market categories in preventive medicine and agricultural genomics.
• Gene-editing therapeutics are transitioning from single-product approvals to platform-scale pipelines across haematology, oncology, and rare disease.
• The data layer — not the wet lab — is becoming the primary competitive moat in enterprise genetics.
• Investors and operators who treat genetics as a niche life-sciences vertical risk missing its horizontal expansion into insurance, food systems, and national security.

Sequencing Economics: The Cost Curve That Changes Everything The economics of DNA sequencing have followed a cost curve steeper than semiconductor transistor density for over a decade, but current market conditions represent a qualitative break, not merely a quantitative one. According to data maintained by the National Human Genome Research Institute, whole-genome sequencing costs have declined from roughly $300 per genome in early 2024 to well below $200 at scale in 2026 — and Illumina's high-throughput configurations are reportedly producing clinical-grade genomes for under $150 per sample when run at maximum capacity. This matters because healthcare payers — the ultimate gatekeepers of clinical adoption — operate on strict cost-effectiveness thresholds. The UK's National Institute for Health and Care Excellence (NICE) and the US Centers for Medicare & Medicaid Services both evaluate diagnostic technologies against incremental cost-per-quality-adjusted-life-year benchmarks. Below a certain price point, population-scale genomic screening becomes not just feasible but economically rational for conditions such as hereditary cancers, pharmacogenomics-guided prescribing, and carrier screening in reproductive health. Illumina remains the dominant sequencing platform vendor by installed base, though competition from Oxford Nanopore Technologies — whose long-read sequencing approach offers distinct advantages in structural variant detection and field-deployable form factors — continues to intensify. Analysis from Gartner's 2026 life-sciences technology assessment notes that the sequencing market is bifurcating into high-throughput centralised facilities (dominated by Illumina's short-read chemistry) and distributed, point-of-care applications where Oxford Nanopore's portable devices hold a structural advantage. Key Market Metrics for Genetics in 2026

Metric	Current Estimate (2026)	Projected (2028)	Source
Global Genetics Market Size	~$78 billion	$95–105 billion	Grand View Research
Whole-Genome Sequencing Cost (High-Throughput)	<$150 per sample	<$100 per sample (projected)	NHGRI
Gene-Editing Therapeutics in Clinical Trials	~85 active programmes globally	120+ (projected)	Nature Biotechnology
Genomic Data Generated Annually	~40 exabytes	100+ exabytes	Illumina corporate estimates
Approved CRISPR-Based Therapies (Global)	2	4–6 (projected)	FDA / EMA
CAGR (Gene Editing Segment, 2024–2028)	—	~18.5%	MarketsandMarkets

Gene Editing Matures: From Single Approvals to Platform Pipelines The approval of Casgevy — developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals — for sickle cell disease and transfusion-dependent beta thalassemia marked a regulatory milestone. But the more consequential development is what has happened since: both companies have expanded their manufacturing infrastructure and begun enrolling patients in broader indications, while next-generation editing companies are advancing platforms that offer greater precision and fewer off-target effects. Beam Therapeutics, which uses base editing to make single-letter changes in DNA without creating double-strand breaks, has multiple programmes in mid-stage clinical development targeting haematological malignancies and liver diseases. Prime Medicine, working with prime editing — a technology capable of all twelve types of point mutations plus small insertions and deletions — is progressing its lead candidate through early-stage trials. According to Nature Biotechnology's most recent pipeline tracker, there are approximately 85 active gene-editing clinical programmes globally as of early 2026, spanning oncology, rare diseases, cardiovascular conditions, and infectious disease. The Manufacturing Bottleneck The critical constraint is no longer scientific proof-of-concept; it is manufacturing scale and cost. Current ex vivo gene-editing therapies — where a patient's cells are extracted, edited, and reinfused — carry production costs that can exceed $500,000 per patient. McKinsey's life-sciences practice estimates that in vivo delivery methods, which edit cells directly inside the body, could reduce per-patient costs by 60–80 per cent once validated at scale. This economic transition is the single most important variable determining whether gene editing becomes a mass-market therapeutic modality or remains confined to ultra-rare diseases. Companies like Intellia Therapeutics are pursuing in vivo CRISPR approaches using lipid nanoparticle delivery systems — the same delivery technology validated by mRNA COVID-19 vaccines. Intellia's transthyretin amyloidosis programme remains one of the most closely watched in the field, with clinical data demonstrating sustained protein knockdown following a single infusion, per the company's investor disclosures. The Data Layer: Where the Real Competitive Moat Is Forming Genetics is, at its core, an information science. For more on [related agentic ai developments](/meta-manus-ai-deal-blocked-2026-china-vetoes-2b-agentic-acqu-27-april-2026). A single whole-genome sequence generates roughly 100 gigabytes of raw data. Multiply that by population-scale programmes — the UK's Genomics England has sequenced over 300,000 genomes; the US All of Us Research Program targets one million participants — and the data management challenge becomes formidable. Cloud hyperscalers have recognised this. Google Cloud's life-sciences division offers genomics-specific compute and storage services, while Amazon Web Services provides purpose-built tools for variant calling and tertiary analysis. Microsoft has invested in AI-driven genomic interpretation through its research partnerships with academic medical centres. This relates directly to broader Genetics trends tracked across the sector: the centre of value creation is migrating from wet-lab instrumentation to the computational layer that interprets, stores, and acts upon genomic information. According to a Forrester Research analysis, enterprise spending on genomic data platforms grew at roughly twice the rate of sequencing hardware spending over the past eighteen months. Per IDC's healthcare data forecast, genomic data is expected to account for more than 30 per cent of all healthcare data by 2028, up from an estimated 12–15 per cent currently. The firms that control the analytical middleware — the software that sits between raw sequence data and clinical or agricultural decision-making — are positioning themselves as the essential infrastructure of the next decade. Competitive Landscape: Platform Vendors, Editing Firms, and Computational Upstarts Platform and Editing Company Comparison

Company	Primary Focus	Key Technology	Competitive Position
Illumina	Sequencing platforms	NovaSeq X Plus (short-read)	Dominant installed base; faces long-read competition
Oxford Nanopore	Portable / long-read sequencing	Nanopore-based real-time sequencing	Structural variant detection; field-deployable
CRISPR Therapeutics	Gene-editing therapeutics	CRISPR-Cas9	First approved CRISPR therapy (Casgevy)
Beam Therapeutics	Base editing therapeutics	Adenine / cytosine base editors	Precision editing without double-strand breaks
Intellia Therapeutics	In vivo gene editing	CRISPR + lipid nanoparticle delivery	Leading in vivo clinical data
Prime Medicine	Prime editing therapeutics	Prime editing (all 12 point mutations)	Broadest theoretical editing versatility
Google Cloud (Life Sciences)	Genomic data infrastructure	Cloud compute, AI interpretation	Scale and ML integration advantages

The competitive landscape is stratifying into three distinct tiers. Tier one comprises the sequencing platform vendors — Illumina and Oxford Nanopore — whose hardware and chemistry define the throughput ceiling. Tier two includes the therapeutic gene-editing firms building clinical pipelines atop CRISPR, base editing, and prime editing platforms. Tier three, and arguably the tier with the most open competitive terrain, consists of the computational and data-infrastructure players: cloud providers, bioinformatics software companies, and hybrid AI-biology firms. A notable dynamic in this third tier is the entry of genetics-focused AI companies that apply large language model architectures to protein structure prediction, variant interpretation, and drug target identification. Google DeepMind's AlphaFold programme demonstrated the feasibility of this approach; newer entrants are commercialising similar capabilities for pharmaceutical and agricultural clients. Regulatory Convergence and Remaining Friction Points One of the sector's most underappreciated developments is the degree to which regulatory frameworks are converging internationally. The US Food and Drug Administration has published updated guidance on human gene therapy products, while the European Medicines Agency has streamlined its advanced therapy medicinal product (ATMP) classification process. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has signalled its intent to create an accelerated pathway for gene therapies targeting conditions with high unmet need. On the data governance side, the picture is more complex. Genomic data occupies an unusual legal position: it is simultaneously health data (subject to HIPAA in the US, GDPR in Europe), potentially identifying information (a genome is the ultimate biometric identifier), and research material with collective implications for biological relatives who never consented to its use. According to PHG Foundation analysis, fewer than 40 per cent of national genomics programmes have comprehensive data-sharing frameworks that address all three dimensions. Based on analysis of regulatory trends across 15 jurisdictions documented by the World Health Organization's genomics governance programme, the trend is towards harmonisation — but the pace varies dramatically between therapeutic regulation (relatively fast) and data governance (significantly slower). Enterprises building genomic data assets need to architect for the strictest plausible regulatory environment, not the current one. What the Next Twelve Months Will Determine The genetics sector in 2026 sits at a juncture where several long-anticipated transitions are occurring simultaneously: sequencing costs are crossing health-economic viability thresholds for population screening; gene-editing therapies are moving from single approvals to pipeline platforms; and the data infrastructure required to operationalise genomic insights at scale is becoming a distinct competitive arena. The open question is not whether these transitions will proceed — the scientific and economic fundamentals are clear — but how quickly health systems, regulators, and enterprise buyers will restructure their operations around them. For investors, the critical variable to monitor is manufacturing cost reduction in gene-editing therapeutics; for enterprise technology leaders, it is the speed at which genomic data platforms mature from research tools into production-grade clinical and agricultural decision systems. The firms that solve the integration problem — connecting raw sequence data to real-time operational decisions — are likely to define the sector's next decade.

Disclosure: Business 2.0 News maintains editorial independence and has no financial relationship with companies mentioned in this article.

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings. Figures independently verified via public financial disclosures and third-party market research.

Timeline: Key Developments

• Late 2023: Casgevy (CRISPR Therapeutics / Vertex) receives first regulatory approvals from the MHRA and FDA for sickle cell disease and beta thalassaemia.
• 2024–2025: Illumina's NovaSeq X series drives whole-genome sequencing costs below $200 at scale; Oxford Nanopore expands clinical-grade long-read applications.
• 2026 (current): Gene-editing pipeline expands to ~85 active clinical programmes globally; cloud hyperscalers deepen genomic data infrastructure offerings; regulatory convergence accelerates across US, EU, and UK.

Related Coverage

• More Genetics Analysis

References

1. [1] Grand View Research. For more on [related ai developments](/rituals-confirms-customer-data-breach-in-cosmetics-sector-20-22-april-2026). (2026). Genomics Market Size, Share & Trends Analysis Report. Grand View Research.
2. [2] National Human Genome Research Institute. (2026). The Cost of Sequencing a Human Genome. NHGRI.
3. [3] CRISPR Therapeutics. (2026). Pipeline and Programs Overview. CRISPR Therapeutics AG.
4. [4] Vertex Pharmaceuticals. (2026). Pipeline Overview. Vertex Pharmaceuticals.
5. [5] Beam Therapeutics. (2026). Our Programs. Beam Therapeutics.
6. [6] Prime Medicine. (2026). Pipeline. Prime Medicine.
7. [7] Intellia Therapeutics. (2026). Investor Relations. Intellia Therapeutics.
8. [8] Illumina. (2026). NovaSeq X Plus Sequencing System. Illumina Inc.
9. [9] Oxford Nanopore Technologies. (2026). Clinical Research Applications. ONT.
10. [10] Genomics England. (2026). Genomics Programmes. Genomics England.
11. [11] National Institutes of Health. (2026). All of Us Research Program. NIH.
12. [12] Google Cloud. (2026). Life Sciences Solutions. Google Cloud.
13. [13] Amazon Web Services. (2026). AWS Genomics. AWS.
14. [14] McKinsey & Company. (2026). Life Sciences Practice Insights. McKinsey.
15. [15] Forrester Research. (2026). Technology and Healthcare Research. Forrester.
16. [16] IDC. (2026). Worldwide Healthcare Data Forecast. IDC.
17. [17] Gartner. (2026). Life Sciences Technology Assessment. Gartner.
18. [18] Nature Biotechnology. (2026). Gene Editing Pipeline Tracker. Springer Nature.
19. [19] PHG Foundation. (2026). Genomic Data Governance Analysis. PHG Foundation, University of Cambridge.
20. [20] World Health Organization. (2026). Genomics Governance Programme. WHO.
21. [21] MarketsandMarkets. (2026). Gene Editing Market Forecast. MarketsandMarkets.
22. [22] US Food and Drug Administration. (2026). Human Gene Therapy Products Guidance. FDA.
23. [23] European Medicines Agency. (2026). Advanced Therapy Medicinal Products. EMA.
24. [24] Google DeepMind. (2026). AlphaFold Programme. DeepMind.